| Year |
Citation |
Score |
| 2020 |
De Zoysa P, Liu J, Toubat O, Choi J, Moon A, Gill PS, Duarte A, Sucov HM, Kumar SR. Delta-like ligand-4 mediated Notch signaling controls proliferation of second heart field progenitor cells by regulating Fgf8 expression. Development (Cambridge, England). PMID 32778568 DOI: 10.1242/Dev.185249 |
0.344 |
|
| 2020 |
Li GX, Zhang S, Liu R, Singh B, Singh S, Quinn DI, Crump G, Gill PS. Tetraspanin18 regulates angiogenesis through VEGFR2 and Notch pathways. Biology Open. PMID 32694189 DOI: 10.1242/Bio.050096 |
0.38 |
|
| 2020 |
Hanna DL, Iqbal S, Habib D, Tsao-Wei DD, Barzi A, Thomas JS, Chiu V, Siddiqi I, Bhavsar RD, Jensen NG, DeLeon C, Lenz H, Gill PS, El-Khoueiry AB. A phase Ib study of sEphB4-HSA combined with first-line chemotherapy in patients (pts) with advanced pancreatic (PC) and biliary cancers (BC). Journal of Clinical Oncology. 38: 4640-4640. DOI: 10.1200/Jco.2020.38.15_Suppl.4640 |
0.343 |
|
| 2019 |
Sagar V, Vatapalli R, Lysy B, Pamarthy S, Anker JF, Rodriguez Y, Han H, Unno K, Stadler WM, Catalona WJ, Hussain M, Gill PS, Abdulkadir SA. EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells. Cell Death & Disease. 10: 801. PMID 31641103 DOI: 10.1038/S41419-019-2042-Y |
0.391 |
|
| 2019 |
Sadeghi S, Li G, Siddiqi I, Sali A, Liang G, Gill I, Pinski JK, Quinn DI, Gill PS. EphB4-EphrinB2 receptor-ligand pair as a novel target in prostate cancer (PC). Journal of Clinical Oncology. 37: 275-275. DOI: 10.1200/Jco.2019.37.7_Suppl.275 |
0.383 |
|
| 2019 |
Li GX, Ma B, Krasnoperov VG, Siddiqi I, Sali A, Liang G, Gill IS, Pinski JK, Quinn DI, Sadeghi S, Gill PS. Abstract 3139: EphB4-EphrinB2 receptor-ligand are downstream effectors and novel targets of PTEN deficient prostate cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3139 |
0.303 |
|
| 2018 |
Thomas JS, Lenz H, Iqbal S, Tsao-Wei DD, Barzi A, Duddalwar V, Cole S, Rehman R, Menendez X, Krasnoperov V, Liu R, Feng Q, Gill PS, El-Khoueiry AB. A first-in-human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular (HCC) and cholangiocarcinoma (CCA). Journal of Clinical Oncology. 36: 285-285. DOI: 10.1200/Jco.2018.36.4_Suppl.285 |
0.315 |
|
| 2018 |
McDaniel NK, Cummings CT, Brand TM, Iida M, Hulse J, Pearson HE, Orbuch RA, Ondracek OJ, Davies KD, Gill P, Wang X, Frye SV, Earp HS, Kimple RJ, Harari PM, et al. Abstract A140: MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A140 |
0.435 |
|
| 2017 |
Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ, Druker BJ, Tyner JW, Gill PS. EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances. 1: 1635-1644. PMID 29296810 DOI: 10.1182/Bloodadvances.2017005694 |
0.413 |
|
| 2017 |
Randolph ME, Cleary MM, Bajwa Z, Svalina MN, Young MC, Mansoor A, Kaur P, Bult CJ, Goros MW, Michalek JE, Xiang S, Keck J, Krasnoperov V, Gill P, Keller C. EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. Plos One. 12: e0183161. PMID 28817624 DOI: 10.1371/Journal.Pone.0183161 |
0.405 |
|
| 2017 |
Shen J, Ha DP, Zhu G, Rangel DF, Kobielak A, Gill PS, Groshen S, Dubeau L, Lee AS. GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice. Proceedings of the National Academy of Sciences of the United States of America. PMID 28461470 DOI: 10.1073/Pnas.1616060114 |
0.335 |
|
| 2016 |
Bhatia S, Hirsch K, Sharma J, Oweida A, Griego A, Keysar S, Jimeno A, Raben D, Krasnoperov V, Gill PS, Pasquale EB, Wang XJ, Karam SD. Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas. Scientific Reports. 6: 38792. PMID 27941840 DOI: 10.1038/Srep38792 |
0.426 |
|
| 2016 |
Bhatia S, Hirsch K, Sharma J, Keysar S, Jimeno A, Gill P, Wang XJ, Karam S. Enhanced Therapeutic Radiosensitization by Targeting EphB4 Receptor in Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology, Biology, Physics. 96: S16. PMID 27675673 DOI: 10.1016/J.Ijrobp.2016.06.052 |
0.303 |
|
| 2016 |
Liang M, Adisetiyo H, Li X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ. Correction: Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. Plos One. 11: e0152243. PMID 26998759 DOI: 10.1371/journal.pone.0152243 |
0.487 |
|
| 2015 |
Wu X, Zahari MS, Ma B, Liu R, Renuse S, Sahasrabuddhe NA, Chen L, Chaerkady R, Kim MS, Zhong J, Jelinek C, Barbhuiya MA, Leal-Rojas P, Yang Y, Kashyap MK, ... ... Gill PS, et al. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget. PMID 26356563 DOI: 10.18632/Oncotarget.5020 |
0.369 |
|
| 2015 |
Zhou B, Wang H, Liu R, Wang M, Deng H, Giglio B, Gill PS, Shan H, Li Z. PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B. Molecular Pharmaceutics. PMID 26288060 DOI: 10.1021/Acs.Molpharmaceut.5B00105 |
0.329 |
|
| 2015 |
Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. Plos One. 10: e0134346. PMID 26270481 DOI: 10.1371/Journal.Pone.0134346 |
0.337 |
|
| 2015 |
Liang M, Adisetiyo H, Liu X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ. Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. Plos One. 10: e0131232. PMID 26196517 DOI: 10.1371/Journal.Pone.0131232 |
0.332 |
|
| 2015 |
Yu H, Liu R, Ma B, Li X, Yen HY, Zhou Y, Krasnoperov V, Xia Z, Zhang X, Bove AM, Buscarini M, Parekh D, Gill IS, Liao Q, Tretiakova M, ... ... Gill PS, et al. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. British Journal of Cancer. PMID 26180925 DOI: 10.1038/Bjc.2015.237 |
0.58 |
|
| 2015 |
Wang H, Li D, Liu S, Liu R, Yuan H, Krasnoperov V, Shan H, Conti PS, Gill PS, Li Z. Small-Animal PET Imaging of Pancreatic Cancer Xenografts Using a 64Cu-Labeled Monoclonal Antibody, MAb159. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 908-13. PMID 25908833 DOI: 10.2967/Jnumed.115.155812 |
0.347 |
|
| 2015 |
Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, et al. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2601-12. PMID 25767293 DOI: 10.1158/1078-0432.Ccr-14-2648 |
0.313 |
|
| 2015 |
Chaudhry P, Singh M, Triche T, Jorapur A, Gill PS, Merchant A. Abstract 2090: GLI3 repressor levels determine Hedgehog pathway activity and predict response to Smoothened antagonist in acute myeloid leukemia Cancer Research. 75: 2090-2090. DOI: 10.1158/1538-7445.Am2015-2090 |
0.401 |
|
| 2015 |
Hotz HG, Bhargava S, Hotz B, Masood R, Gill PS, Buhr HJ. Der Angiogenese-Inhibitor IM862 verbessert das Überleben beim experimentellen Pankreaskarzinom auch nach verzögertem Therapiebeginn Zeitschrift Fur Gastroenterologie. 41: 207-208. DOI: 10.1007/978-3-642-18547-2_64 |
0.417 |
|
| 2014 |
Ferguson BD, Tretiakova MS, Lingen MW, Gill PS, Salgia R. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors (Chur, Switzerland). 32: 202-6. PMID 25391996 DOI: 10.3109/08977194.2014.980904 |
0.41 |
|
| 2014 |
Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. Plos One. 9: e105326. PMID 25148033 DOI: 10.1371/Journal.Pone.0105326 |
0.661 |
|
| 2014 |
Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Research. 74: 5152-64. PMID 25136066 DOI: 10.1158/0008-5472.Can-14-0294 |
0.37 |
|
| 2014 |
Liu S, Li D, Guo J, Canale N, Li X, Liu R, Krasnoperov V, Gill PS, Conti PS, Shan H, Li Z. Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft. Molecular Pharmaceutics. 11: 3974-9. PMID 24978094 DOI: 10.1021/Mp500307T |
0.572 |
|
| 2014 |
Li D, Liu S, Liu R, Park R, Yu H, Krasnoperov V, Gill PS, Li Z, Shan H, Conti PS. Axl-targeted cancer imaging with humanized antibody h173. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 16: 511-8. PMID 24424460 DOI: 10.1007/S11307-013-0714-Z |
0.371 |
|
| 2014 |
Pan C, Zhang H, Tepper C, Ghosh P, Kuslak-Meyer S, Airhart S, Gill P, Gandara D, Liu E, White RdV. Abstract LB-32: Patient-derived xenograft (PDX) paraclinical platform to guide precision medicine in urothelial cancer Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-32 |
0.342 |
|
| 2014 |
Brand TM, Iida M, Corrigan KL, Luthar N, Hornung M, Toulany M, Gill P, Salgia R, Wheeler DL. Abstract LB-215: The TAM family of receptor tyrosine kinases play a role in acquired resistance to cetuximab Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-215 |
0.396 |
|
| 2014 |
Yang-Kolodji GW, Liu R, Mehta A, Gill P, Tripathy D. Abstract 2601: EphB4/EphrinB2 targeting increases the efficacy of cisplatin in triple negative breast cancer Cancer Research. 74: 2601-2601. DOI: 10.1158/1538-7445.Am2014-2601 |
0.384 |
|
| 2014 |
Kim MY, Jorapur A, McManus AR, Liu R, Krasnoperov V, Naga K, Gill PS, Merchant A. Abstract 1758: Targeting EphB4 with a novel antibody in acute leukemia Cancer Research. 74: 1758-1758. DOI: 10.1158/1538-7445.Am2014-1758 |
0.403 |
|
| 2013 |
Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra SK, Krasnoperov V, Dong D, Liu S, Li D, Zhu G, Louie S, Conti PS, Li Z, Lee AS, ... Gill PS, et al. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6802-11. PMID 24048331 DOI: 10.1158/1078-0432.Ccr-13-1106 |
0.631 |
|
| 2013 |
Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, ... ... Gill PS, et al. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. Plos One. 8: e67668. PMID 23844053 DOI: 10.1371/Journal.Pone.0067668 |
0.372 |
|
| 2013 |
Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V. EphB4 as a therapeutic target in mesothelioma. Bmc Cancer. 13: 269. PMID 23721559 DOI: 10.1186/1471-2407-13-269 |
0.388 |
|
| 2013 |
Liu S, Li D, Park R, Liu R, Xia Z, Guo J, Krasnoperov V, Gill PS, Li Z, Shan H, Conti PS. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 1094-100. PMID 23667241 DOI: 10.2967/Jnumed.112.116822 |
0.326 |
|
| 2013 |
Li D, Liu S, Liu R, Park R, Hughes L, Krasnoperov V, Gill PS, Li Z, Shan H, Conti PS. Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring. Molecular Pharmaceutics. 10: 329-36. PMID 23211050 DOI: 10.1021/Mp300461B |
0.373 |
|
| 2013 |
Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, ... ... Gill P, et al. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Research. 73: 184-94. PMID 23100466 DOI: 10.1158/0008-5472.Can-12-0915 |
0.654 |
|
| 2013 |
Duarte A, Quaresma J, Trindade A, Tripathy P, Liu X, Krasnoperov V, Liu R, Gill PS. Abstract 540: Role of EphB4-EphrinB2 as novel target in Her2 positive breast cancer. Cancer Research. 73: 540-540. DOI: 10.1158/1538-7445.Am2013-540 |
0.414 |
|
| 2013 |
Liu R, Yen H, Masood R, Sinha U, El-Khoueiry A, Liu S, Gitlitz B, Gill PS. Abstract 4356: EphB4 as a novel therapeutic target for head-neck SCC. Cancer Research. 73: 4356-4356. DOI: 10.1158/1538-7445.Am2013-4356 |
0.469 |
|
| 2013 |
Liang M, Adisetiyo HA, Li X, Liu R, Gill PS, Roy-Burman P. Abstract 4087: Androgen receptor splice variants in mouse prostate cancer cell lines: altered distribution in lines derived from castration-resistant tumors relative to those primary tumors. Cancer Research. 73: 4087-4087. DOI: 10.1158/1538-7445.Am2013-4087 |
0.608 |
|
| 2012 |
He M, Zhang W, Bakken T, Schutten M, Toth Z, Jung JU, Gill P, Cannon M, Gao SJ. Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2. Cancer Research. 72: 3582-92. PMID 22593192 DOI: 10.1158/0008-5472.Can-11-2876 |
0.447 |
|
| 2012 |
Trindade A, Djokovic D, Gigante J, Badenes M, Pedrosa AR, Fernandes AC, Lopes-da-Costa L, Krasnoperov V, Liu R, Gill PS, Duarte A. Low-dosage inhibition of Dll4 signaling promotes wound healing by inducing functional neo-angiogenesis. Plos One. 7: e29863. PMID 22279550 DOI: 10.1371/Journal.Pone.0029863 |
0.396 |
|
| 2012 |
Liu R, Trindade A, Sun Z, Kumar R, Weaver FA, Krasnoperov V, Naga K, Duarte A, Gill PS. Inhibition of Notch signaling by Dll4-Fc promotes reperfusion of acutely ischemic tissues. Biochemical and Biophysical Research Communications. 418: 173-9. PMID 22252294 DOI: 10.1016/J.Bbrc.2012.01.002 |
0.33 |
|
| 2012 |
Agarwal VR, Joshi A, Venkataraman M, Bhatia D, Bose J, Kolla LS, Gill P, Sharma S. Abstract 3759: P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of Rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) as a new therapeutic option for Kras mutated non small cell lung cancer (NSCLC) Cancer Research. 72: 3759-3759. DOI: 10.1158/1538-7445.Am2012-3759 |
0.362 |
|
| 2012 |
Agarwal VR, Joshi A, Venkataraman M, Desai N, Bhatia D, Chaudhari S, Bose J, Kolla LS, Deore V, Yewalkar N, Kumar S, Sharma R, Damre A, More A, Gill P, et al. Abstract 3742: P7170: A potent and oral phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) inhibitor with anti-tumor and anti-angiogenic activity Cancer Research. 72: 3742-3742. DOI: 10.1158/1538-7445.Am2012-3742 |
0.415 |
|
| 2012 |
Hasina R, Mutreja K, Kawada I, Kanteti R, Arif Q, Liu R, Li X, Zhou Y, Hyjek E, Lingen MW, Mueller J, Waxman I, Villaflor V, Ferguson M, Vokes EE, ... Gill P, et al. Abstract 1861: EPHB4 as a potential therapeutic target for esophageal cancer Cancer Research. 72: 1861-1861. DOI: 10.1158/1538-7445.Am2012-1861 |
0.623 |
|
| 2011 |
Duarte A, Badenes M, Trindade A, Liu R, Gill PS. Abstract LB-285: Blocking Dll4/Notch signaling inhibits development of chronic colitis-associated colorectal cancer in mice Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-285 |
0.434 |
|
| 2011 |
Passarini J, Cleary JP, Kumar P, Newton T, Sharma M, Sharma C, Panunzalan RR, Gill P, Sharma S, Srivastava R, Shankar S, Sharma JP. Abstract 3306: Screening potential drug candidates for treatment of glioblastoma patients utilizing an in-vivo mouse/ rat model system Cancer Research. 71: 3306-3306. DOI: 10.1158/1538-7445.Am2011-3306 |
0.37 |
|
| 2011 |
Hasina R, Kanade G, Yala S, Mollberg N, Muller J, Surati M, Kanteti R, Husain A, Posner M, Waxman I, Vigneswaran W, Ferguson M, Villaflor V, Vokes EE, Gill P, et al. Abstract 1625: Role of EphB4 in esophageal cancer: Expression, amplification, and therapeutic inhibition Cancer Research. 71: 1625-1625. DOI: 10.1158/1538-7445.Am2011-1625 |
0.442 |
|
| 2011 |
Gill P. 188 VEGF-Notch-EphrinB2 Pathways in AIDS-Related Kaposiʼs Sarcoma Jaids Journal of Acquired Immune Deficiency Syndromes. 56: 79. DOI: 10.1097/01.Qai.0000397370.70578.3E |
0.334 |
|
| 2010 |
Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS, Duarte A. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. Bmc Cancer. 10: 641. PMID 21092311 DOI: 10.1186/1471-2407-10-641 |
0.623 |
|
| 2010 |
Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, ... ... Gill PS, et al. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Molecular Cancer Therapeutics. 9: 2377-88. PMID 20682653 DOI: 10.1158/1535-7163.Mct-10-0200 |
0.392 |
|
| 2010 |
Liu R, Gong M, Li X, Zhou Y, Gao W, Tulpule A, Chaudhary PM, Jung J, Gill PS. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood. 116: 297-305. PMID 20442363 DOI: 10.1182/Blood-2009-12-257154 |
0.677 |
|
| 2010 |
Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. The American Journal of Pathology. 176: 2029-38. PMID 20133814 DOI: 10.2353/Ajpath.2010.090755 |
0.791 |
|
| 2010 |
Liu R, Li X, Tulpule A, Zhou Y, Scehnet JS, Zhang S, Lee JS, Chaudhary PM, Jung J, Gill PS. KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood. 115: 887-95. PMID 19965636 DOI: 10.1182/Blood-2009-08-236745 |
0.794 |
|
| 2010 |
He S, Kumar SR, Zhou P, Krasnoperov V, Ryan SJ, Gill PS, Hinton DR. Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro. Investigative Ophthalmology & Visual Science. 51: 543-52. PMID 19696168 DOI: 10.1167/Iovs.09-3475 |
0.373 |
|
| 2010 |
Spannuth WA, Krasnoperov V, Liu R, Nick AM, Lin YG, Merritt W, Coleman RL, Gill PS, Sood AK. Abstract 335: Therapeutic targeting of EphB4 with a novel monoclonal antibody Cancer Research. 70: 335-335. DOI: 10.1158/1538-7445.Am10-335 |
0.398 |
|
| 2009 |
Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, Manchanda PK, Ladner RD, Hawes D, Weaver FA, Beart RW, Singh G, Nguyen C, Kahn M, Gill PS. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Research. 69: 3736-45. PMID 19366806 DOI: 10.1158/0008-5472.Can-08-3232 |
0.794 |
|
| 2009 |
Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR, Gill PS. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood. 113: 254-63. PMID 18836096 DOI: 10.1182/Blood-2008-02-140020 |
0.793 |
|
| 2008 |
Benedito R, Trindade A, Hirashima M, Henrique D, da Costa LL, Rossant J, Gill PS, Duarte A. Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. Bmc Developmental Biology. 8: 117. PMID 19087347 DOI: 10.1186/1471-213X-8-117 |
0.366 |
|
| 2008 |
Yavrouian EJ, Sinha UK, Rice DH, Salam MT, Gill PS, Masood R. The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma Archives of Otolaryngology - Head and Neck Surgery. 134: 985-991. PMID 18794445 DOI: 10.1001/Archotol.134.9.985 |
0.339 |
|
| 2008 |
Trindade A, Kumar SR, Scehnet JS, Lopes-da-Costa L, Becker J, Jiang W, Liu R, Gill PS, Duarte A. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood. 112: 1720-9. PMID 18559979 DOI: 10.1182/Blood-2007-09-112748 |
0.781 |
|
| 2007 |
Ku TK, Nguyen DC, Karaman M, Gill P, Hacia JG, Crowe DL. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. Molecular Cancer Research : McR. 5: 351-62. PMID 17426250 DOI: 10.1158/1541-7786.Mcr-06-0238 |
0.38 |
|
| 2007 |
Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. British Journal of Cancer. 96: 1083-91. PMID 17353927 DOI: 10.1038/Sj.Bjc.6603642 |
0.788 |
|
| 2007 |
Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A, Gill PS. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood. 109: 4753-60. PMID 17311993 DOI: 10.1182/Blood-2006-12-063933 |
0.792 |
|
| 2007 |
Choi WW, Scehnet JS, Kumar SR, Lee CC, Schuckman A, Klumpp DJ, Stein JP, Gill PS. 762: Differential Regulation of EPHB4 and EPHB2 Receptor Tyrosine Kinases in Normal Bladder and Bladder Transitional Cell Carcinoma Journal of Urology. 177: 256-256. DOI: 10.1016/S0022-5347(18)31002-4 |
0.312 |
|
| 2006 |
Sinha UK, Mazhar K, Chinn SB, Dhillon VK, Liu L, Masood R, Rice DH, Gill PS. The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma. Archives of Otolaryngology--Head & Neck Surgery. 132: 1053-9. PMID 17043250 DOI: 10.1001/Archotol.132.10.1053 |
0.308 |
|
| 2006 |
Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, Weaver FA, Gill PS. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. The American Journal of Pathology. 169: 279-93. PMID 16816380 DOI: 10.2353/Ajpath.2006.050889 |
0.796 |
|
| 2006 |
Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, Singh J, Xia G, Broek D, Schönthal AH, Gill PS. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. International Journal of Cancer. Journal International Du Cancer. 119: 1236-48. PMID 16615113 DOI: 10.1002/Ijc.21926 |
0.463 |
|
| 2006 |
Levine AM, Tulpule A, Quinn DI, Gorospe G, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1712-9. PMID 16520466 DOI: 10.1200/Jco.2005.03.4801 |
0.381 |
|
| 2006 |
Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP, Gill PS. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. The Journal of Urology. 175: 1245-52. PMID 16515971 DOI: 10.1016/S0022-5347(05)00736-6 |
0.459 |
|
| 2006 |
Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, Gill PS. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood. 107: 2330-8. PMID 16322467 DOI: 10.1182/Blood-2005-04-1655 |
0.453 |
|
| 2006 |
Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, Hassanieh L, Smith DL, Buscarini M, Broek D, Quinn DI, Weaver FA, Gill PS. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 25: 769-80. PMID 16205642 DOI: 10.1038/Sj.Onc.1209108 |
0.474 |
|
| 2006 |
Subramanyan RK, Hassanieh L, Singh J, Gill P, Weaver F. Delta-like ligand-4 induces angiogenesis at sites of neovascularization in the adult Journal of the American College of Surgeons. 203: S100-S101. DOI: 10.1016/J.Jamcollsurg.2006.05.264 |
0.748 |
|
| 2005 |
He S, Ding Y, Zhou J, Krasnoperov V, Zozulya S, Kumar SR, Ryan SJ, Gill PS, Hinton DR. Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization. Investigative Ophthalmology & Visual Science. 46: 4772-9. PMID 16303978 DOI: 10.1167/Iovs.05-0502 |
0.336 |
|
| 2005 |
Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, ... ... Gill PS, et al. EphB4 expression and biological significance in prostate cancer. Cancer Research. 65: 4623-32. PMID 15930280 DOI: 10.1158/0008-5472.Can-04-2667 |
0.363 |
|
| 2005 |
Hotz HG, Hines OJ, Masood R, Hotz B, Foitzik T, Buhr HJ, Gill PS, Reber HA. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer Surgery. 137: 192-199. PMID 15674201 DOI: 10.1016/J.SURG.2004.07.015 |
0.396 |
|
| 2005 |
Masood R, Xia G, Smith DL, Scalia P, Still JG, Tulpule A, Gill PS. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood. 105: 1310-8. PMID 15471957 DOI: 10.1182/Blood-2004-03-0933 |
0.411 |
|
| 2005 |
Gill PS. Retrovirology. 2: S43. DOI: 10.1186/1742-4690-2-S1-S43 |
0.432 |
|
| 2004 |
Frankel AE, Gill PS. VEGF and myeloid leukemias. Leukemia Research. 28: 675-7. PMID 15158088 DOI: 10.1016/J.Leukres.2003.12.013 |
0.363 |
|
| 2004 |
Wang JF, Liu ZY, Anand AR, Zhang X, Brown LF, Dezube BJ, Gill P, Ganju RK. Alpha-chemokine-mediated signal transduction in human Kaposi's sarcoma spindle cells. Biochimica Et Biophysica Acta. 1691: 129-39. PMID 15110993 DOI: 10.1016/J.Bbamcr.2004.01.002 |
0.403 |
|
| 2003 |
Sinha UK, Kundra A, Scalia P, Smith DL, Parsa B, Masood R, Gill PS. Expression of EphB4 in head and neck squamous cell carcinoma. Ear, Nose, & Throat Journal. 82: 866, 869-70, 887. PMID 14661437 DOI: 10.1177/014556130308201113 |
0.413 |
|
| 2003 |
Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. International Journal of Cancer. 104: 603-10. PMID 12594815 DOI: 10.1002/Ijc.10996 |
0.411 |
|
| 2002 |
Hotz HG, Gill PS, Masood R, Hotz B, Buhr HJ, Foitzik T, Hines OJ, Reber HA, Fernandez Del-Castillo C, Neoptolemos J, Fink V. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer Journal of Gastrointestinal Surgery. 6: 159-166. PMID 11992800 DOI: 10.1016/S1091-255X(01)00040-3 |
0.448 |
|
| 2002 |
Masood R, Cesarman E, Smith DL, Gill PS, Flore O. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. The American Journal of Pathology. 160: 23-9. PMID 11786394 DOI: 10.1016/S0002-9440(10)64344-1 |
0.423 |
|
| 2002 |
Tulpule A, Sherrod A, Dharmapala D, Young LL, Espina BM, Sanchez MN, Gill PS, Levine AM. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leukemia Research. 26: 121-7. PMID 11755462 DOI: 10.1016/S0145-2126(01)00113-8 |
0.317 |
|
| 2001 |
Masood R, Gordon EM, Whitley MD, Wu BW, Cannon P, Evans L, Anderson WF, Gill P, Hall FL. Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. International Journal of Molecular Medicine. 8: 335-43. PMID 11562769 DOI: 10.3892/Ijmm.8.4.335 |
0.39 |
|
| 2001 |
Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 98: 1904-13. PMID 11535528 DOI: 10.1182/Blood.V98.6.1904 |
0.449 |
|
| 2001 |
Hotz HG, Gill PS, Masood R, Hotz B, Buhr HJ, Foitzik T, Hines OJ, Reber HA. Specific targeting of tumor vasculature by DT-VEGF fusion protein reduces angiogenesis and growth of pancreatic cancer Gastroenterology. 120: A105-A106. DOI: 10.1016/S0016-5085(08)80517-3 |
0.4 |
|
| 2000 |
Cai J, Zheng T, Masood R, Smith DL, Hinton DR, Kim CN, Fang G, Bhalla K, Gill PS. Paclitaxel Induces Apoptosis in AIDS-Related Kaposi's Sarcoma Cells. Sarcoma. 4: 37-45. PMID 18521433 DOI: 10.1155/S1357714X00000074 |
0.425 |
|
| 2000 |
Munshi N, Groopman JE, Gill PS, Ganju RK. c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells. Journal of Immunology (Baltimore, Md. : 1950). 164: 1169-74. PMID 10640727 DOI: 10.4049/Jimmunol.164.3.1169 |
0.413 |
|
| 2000 |
Masood R, Nagpal S, Zheng T, Cai J, Tulpule A, Smith DL, Gill PS. Kaposi sarcoma is a therapeutic target for vitamin D3receptor agonist Blood. 96: 3188-3194. DOI: 10.1182/Blood.V96.9.3188.H8003188_3188_3194 |
0.369 |
|
| 1999 |
Kundu RK, Sangiorgi F, Wu LY, Pattengale PK, Hinton DR, Gill PS, Maxson R. Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood. 94: 275-82. PMID 10381523 DOI: 10.1182/Blood.V94.1.275.413A30_275_282 |
0.341 |
|
| 1999 |
Masood R, McGarvey ME, Zheng T, Cai J, Arora N, Smith DL, Sloane N, Gill PS. Antineoplastic Urinary Protein Inhibits Kaposi’s Sarcoma and Angiogenesis In Vitro and In Vivo Blood. 93: 1038-1044. DOI: 10.1182/Blood.V93.3.1038.403A14_1038_1044 |
0.436 |
|
| 1998 |
McGarvey ME, Tulpule A, Cai J, Zheng T, Masood R, Espina B, Arora N, Smith DL, Gill PS. Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. Current Opinion in Oncology. 10: 413-21. PMID 9800111 DOI: 10.1097/00001622-199809000-00008 |
0.377 |
|
| 1998 |
Willis MC, Collins BD, Zhang T, Green LS, Sebesta DP, Bell C, Kellogg E, Gill SC, Magallanez A, Knauer S, Bendele RA, Gill PS, Janjić N, Collins B. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjugate Chemistry. 9: 573-82. PMID 9736491 DOI: 10.1021/Bc980002X |
0.342 |
|
| 1998 |
Gill PS, Tsai YC, Rao AP, Spruck CH, Zheng T, Harrington WA, Cheung T, Nathwani B, Jones PA. Evidence for multiclonality in multicentric Kaposi's sarcoma. Proceedings of the National Academy of Sciences of the United States of America. 95: 8257-61. PMID 9653174 DOI: 10.1073/Pnas.95.14.8257 |
0.333 |
|
| 1998 |
Ganju RK, Munshi N, Nair BC, Liu Z, Gill P, Groopman JE. Human Immunodeficiency Virus Tat Modulates the Flk-1/KDR Receptor, Mitogen-Activated Protein Kinases, and Components of Focal Adhesion in Kaposi’s Sarcoma Cells Journal of Virology. 72: 6131-6137. PMID 9621077 DOI: 10.1128/Jvi.72.7.6131-6137.1998 |
0.37 |
|
| 1998 |
Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi JP, Shriver SL, Suckow CW, Gill PS. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 1444-9. PMID 9552050 DOI: 10.1200/Jco.1998.16.4.1444 |
0.349 |
|
| 1997 |
Gill PS, McLaughlin T, Espina BM, Tulpule A, Louie S, Lunardi-Iskandar Y, Gallo RC. Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma. Journal of the National Cancer Institute. 89: 1797-802. PMID 9392621 DOI: 10.1093/Jnci/89.23.1797 |
0.323 |
|
| 1997 |
Jie C, Tulpule A, Zheng T, Masood R, Espina B, Gill PS. Treatment of epidemic (AIDS-related) Kaposi's sarcoma. Current Opinion in Oncology. 9: 433-9. PMID 9327221 DOI: 10.1097/00001622-199709050-00007 |
0.342 |
|
| 1997 |
Liu ZY, Ganju RK, Wang JF, Ona MA, Hatch WC, Zheng T, Avraham S, Gill P, Groopman JE. Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells. Journal of Clinical Investigation. 99: 1798-1804. PMID 9120025 DOI: 10.1172/Jci119344 |
0.422 |
|
| 1997 |
Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proceedings of the National Academy of Sciences of the United States of America. 94: 979-84. PMID 9023368 DOI: 10.1073/pnas.94.3.979 |
0.341 |
|
| 1997 |
Cai J, Zheng T, Lotz M, Zhang Y, Masood R, Gill P. Glucocorticoids Induce Kaposi's Sarcoma Cell Proliferation Through the Regulation of Transforming Growth Factor-β Blood. 89: 1491-1500. DOI: 10.1182/Blood.V89.5.1491.1491_1491_1500 |
0.326 |
|
| 1997 |
Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. VASCULAR ENDOTHELIAL GROWTH FACTOR/VASCULAR PERMEABILITY FACTOR (VEGF/VPF) IS AN AUTOCRINE GROWTH FACTOR FOR AIDS-KS Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 14: A33. DOI: 10.1097/00042560-199704010-00108 |
0.322 |
|
| 1997 |
Husain SR, Gill P, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Molecular Medicine. 3: 327-338. DOI: 10.1007/Bf03401811 |
0.339 |
|
| 1996 |
Mori N, Gill P, Mougdil T, Murakami S, Eto S, Prager D. Interleukin-10 gene expression in adult T-cell leukemia Blood. 88: 1035-1045. DOI: 10.1182/Blood.V88.3.1035.Bloodjournal8831035 |
0.301 |
|
| 1995 |
Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. The New England Journal of Medicine. 332: 1744-8. PMID 7760890 DOI: 10.1056/Nejm199506293322603 |
0.315 |
|
| 1995 |
Lunardi-Iskandar Y, Gill P, Lam VH, Zeman RA, Michaels F, Mann DL, Reitz MS, Kaplan M, Berneman ZN, Carter D, Bryant JL, Gallo RC. Isolation and characterization of an immortal neoplastic cell line (KS Y-1) from AIDS-associated Kaposi's sarcoma Journal of the National Cancer Institute. 87: 974-981. PMID 7629884 DOI: 10.1093/Jnci/87.13.974 |
0.366 |
|
| 1994 |
Kumar SR, Gill PS, Wagner DG, Dugel PU, Moudgil T, Rao NA. Human T-cell lymphotropic virus type I-associated retinal lymphoma. A clinicopathologic report. Archives of Ophthalmology (Chicago, Ill. : 1960). 112: 954-9. PMID 8031276 DOI: 10.1001/Archopht.1994.01090190102028 |
0.308 |
|
| 1993 |
Masood R, Cai J, Law R, Gill P. AIDS-associated Kaposi's sarcoma pathogenesis, clinical features, and treatment. Current Opinion in Oncology. 5: 831-834. PMID 8218495 DOI: 10.1097/00001622-199309000-00010 |
0.341 |
|
| 1991 |
Gill PS. Pathogenesis of HIV-related malignancies Current Opinion in Oncology. 3: 867-871. PMID 1751580 DOI: 10.1097/00001622-199110000-00010 |
0.336 |
|
| 1991 |
Gill PS, Rarick M, McCutchan JA, Slater L, Parker B, Muchmore E, Bernstein-Singer M, Akil B, Espina BM, Krailo M, Levine A. Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial The American Journal of Medicine. 90: 427-433. DOI: 10.1016/0002-9343(91)80081-V |
0.321 |
|
| 1990 |
Dugel PU, Gill PS, Frangieh GT, Rao NA. Ocular adnexal Kaposi's sarcoma in acquired immunodeficiency syndrome American Journal of Ophthalmology. 110: 500-503. PMID 2240135 DOI: 10.1016/S0002-9394(14)77872-9 |
0.321 |
|
| 1990 |
Gill P, Rarick M, Bernstein-Singer M, Harb M, Espina BM, Shaw V, Levine A. Treatment of advanced Kaposi's Sarcoma using a combination of bleomycin and vincristine American Journal of Clinical Oncology. 13: 315-319. PMID 1696066 DOI: 10.1097/00000421-199008000-00010 |
0.302 |
|
| 1989 |
Shibata D, Brynes RK, Rabinowitz A, Hanson CA, Slovak ML, Spira TJ, Gill P. Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1) Annals of Internal Medicine. 111: 871-875. PMID 2573306 DOI: 10.7326/0003-4819-111-11-871 |
0.304 |
|
| 1987 |
Levine AM, Gill PS, Muggia F. Malignancies in the acquired immunodeficiency syndrome. Current Problems in Cancer. 11: 209-55. PMID 3608570 DOI: 10.1016/S0147-0272(87)80008-9 |
0.326 |
|
| 1987 |
Turner RR, Meyer PR, Taylor CR, Gill PS, Hofman FM, Nichols P, Rasheed S, Levine AM. Immunohistology of persistent generalized lymphadenopathy. Evidence for progressive lymph node abnormalities in some patients. American Journal of Clinical Pathology. 88: 10-9. PMID 3300263 DOI: 10.1093/Ajcp/88.1.10 |
0.306 |
|
| 1986 |
Gill PS, Meyer PR, Pavlova Z, Levine AM. B cell acute lymphocytic leukemia in adults. Clinical, morphologic, and immunologic findings Journal of Clinical Oncology. 4: 737-743. PMID 3486255 DOI: 10.1200/Jco.1986.4.5.737 |
0.305 |
|
| 1985 |
Gill PS, Levine AM, Meyer PR, Boswell WD, Burkes RL, Parker JW, Hofman FM, Dworsky RL, Lukes RJ. Primary central nervous system lymphoma in homosexual men. Clinical, immunologic, and pathologic features. The American Journal of Medicine. 78: 742-8. PMID 3873174 DOI: 10.1016/0002-9343(85)90277-3 |
0.302 |
|
| Show low-probability matches. |